Breaking News

Report Reveals Cell & Gene Therapy CDMO Market to Reach $18.6B by 2032

New partnerships with pharma, biopharma companies have enabled CDMOs to fuel the rapid growth of capabilities and capacities.

A new report from Prophecy Market Insights (PMI) reveals that the cell and gene therapy CDMO market is expected to reach $18.6 billion by 2032. According to the report, new partnerships with pharmaceutical and biotechnology companies have enabled CDMO players to fuel the rapid growth of capabilities and capacities by helping industries succeed in drug and vaccine production. Integration of clinical trial services is expected to become a new trend for CDMOs as they enter high-value, low-volume...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters